Logo

NeoGenesis Broadens Cardiovascular Drug Research for Mitsubishi

Sep 10, 2002

NEW YORK, Sept. 10-The chemical genomics company NeoGenesis has successfully identified lead compounds for Mitsubishi Pharma and will continue to develop a small molecule for its Japanese partner, the company said today.

 

This research builds upon a deal struck in August 2001, whereby NeoGenesis agreed to screen compounds and identify potential drugs for cardiovascular disease targets supplied by Mitsubishi.

 

NeoGenesis CEO Satish Jindel said that this research program was challenging, and that no small molecules had previously been identified as strong drug candidates for this target.

 

The company will now develop the compound through preclinical stages, he said. In return, NeoGenesis received an undisclosed milestone payment from Mitsubishi.

 

NeoGenesis is privately held, and based in Cambridge, Mass.

Breaking News
The Scan

Genes Linked to White-Tailed Jackrabbits' Winter Coat Color Change

Climate change, the researchers noted in Science, may lead to camouflage mismatch and increase predation of white-tailed jackrabbits.

Adenine Base Editor Targets SCID Mutation in New Study

Researchers from the University of California, Los Angeles, report in Cell that adenine base editing was able to produce functional T lymphocytes in a model of severe combined immune deficiency.

Researchers Find Gene Affecting Alkaline Sensitivity in Plants

Researchers from the Chinese Academy of Science have found a locus affecting alkaline-salinity sensitivity, which could aid in efforts to improve crop productivity, as they report in Science.

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.